Judy Garber

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

Sebastian M. Armasu, Jaana M. Hartikainen, A. Whittemore, 2013, Nature Genetics.

Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy.

E. Winer, R. Gelman, J. Garber, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

A. Tutt, H. Earl, N. Loman, 2010, The Lancet.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

E. Winer, J. Cuzick, A. Tutt, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Mark Robson, James Carmichael, Judy E Garber, 2010, The Lancet.

Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.

A. Tutt, N. Loman, J. Garber, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.